Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $33 to $27.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $50.00 | Outperform | Wolfe Research |
| 10/16/2024 | $43.00 | Buy | UBS |
| 10/10/2024 | $40.00 | Buy | Guggenheim |
| 2/23/2024 | $30.00 → $33.00 | Buy | Needham |
| 1/18/2023 | Outperform → Mkt Perform | Raymond James | |
| 1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
| 3/2/2022 | $52.00 → $44.00 | Overweight | Stephens & Co. |
| 3/1/2022 | $62.00 → $34.00 | Outperform | Raymond James |
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a recent trend of the investment firm adjusting its portfolio. The HOOD Trade: Ark Invest’s decision to trim its position in Robinhood was executed through three of its ETFs. The ARK Fintech Innovation ETF (NYSE:ARKF) sold 31,827 shares, while the ARK Innovation ETF (NYSE:ARKK) and the ARK Next Generation Internet ETF (NYSE:ARKW) offloaded 215,675 and 76,299 shares respectively. Based on Robinhood’s closing price of $23.42 on Monday, the total value of the shares sold is approximately $7.6 mill
4 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 0 1 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 1 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.25, with a high estimate of $33.00 and a low estimate of $21.00. A negative shift in sentiment is eviden
Grew total revenue to $115.9 million, an increase of 29% Grew testing revenue to $109.5 million, an increase of 34% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing business continued during the third quarter as we delivered record revenue along with profitability and cash generation," said Marc Stapley, Veracyte's chief executive officer. "Looking ahead, we see tremendous opportunities for further market penetration for both Decipher and Afirma, to serve even more patients and their physicians. We also remain excited about our focused p
Veracyte, Inc. (NASDAQ:VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. UBS Healthcare Conference – Rancho Palos Verdes, CA Fireside Chat on November 12th at 2:45 p.m. Eastern Time Guggenheim Inaugural Healthcare Innovation Conference – Boston, MA Fireside Chat on November 13th at 3:00 p.m. Eastern Time Wolfe Research Healthcare Conference – New York, NY Fireside Chat on November 19th at 1:40 p.m. Eastern Time Stephens Annual Investor Conference – Nashville, TN Fireside Chat on November 20th at 4:00 p.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte'
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/kzh3s376. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte
144 - VERACYTE, INC. (0001384101) (Subject)
144 - VERACYTE, INC. (0001384101) (Subject)
10-Q - VERACYTE, INC. (0001384101) (Filer)
SC 13G - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00
UBS initiated coverage of Veracyte with a rating of Buy and set a new price target of $43.00
Guggenheim initiated coverage of Veracyte with a rating of Buy and set a new price target of $40.00
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac
Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a
Veracyte, Inc. (NASDAQ:VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately. "We are thrilled to welcome Eliav Barr to our board," said Marc Stapley, Veracyte's chief executive officer. "Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology." Dr. Barr has built his distinguished career at Merck Research Labo
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
Grew total revenue to $115.9 million, an increase of 29% Grew testing revenue to $109.5 million, an increase of 34% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing business continued during the third quarter as we delivered record revenue along with profitability and cash generation," said Marc Stapley, Veracyte's chief executive officer. "Looking ahead, we see tremendous opportunities for further market penetration for both Decipher and Afirma, to serve even more patients and their physicians. We also remain excited about our focused p
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/kzh3s376. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte
Grew total revenue to $114.4 million, an increase of 27% Grew testing revenue by 31% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the second quarter ended June 30, 2024. "Our exceptional second quarter results are a testament to the strength and robustness of Decipher and Afirma," said Marc Stapley, Veracyte's chief executive officer. "With both tests clearly gaining share in their respective markets and plenty of headroom for durable future expansion, our confidence in their long-term prospects continues to grow. Meanwhile, our positive cash generation and class-leading profitability profile are fueling a portf